A Phase 4 interventional study of simvastatin and Comparator: Placebo in Systemic Lupus Erythematosus, sponsored by Organon and Co. Terminated. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-23.
Sponsored by Organon and Co · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Women with Systemic Lupus Erythematosus (SLE) are prone to cardiovascular disease. Early detection of improvement of endothelial function with simvastatin could be a clue for future intervention trials.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
This study's enrollment of 4 is below the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Browse Lupus Erythematosus, Systemic studies →Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Arm 1: Drug
Drug: simvastatin
Arm 2: Placebo
Drug: Comparator: Placebo
simvastatin 20mg daily at nights for 12 weeks. Tablets
Also known as: Zocor, MK0733
placebo daily at nights for 12 weeks. Tablets
Change From Baseline in Endothelial Thickness After 12 Weeks of Treatment.
The study was terminated; no outcome measure data analyses were conducted.
Time frame: Baseline and 12 weeks
Change in Total Cholesterol From Baseline at Week 12
The study was terminated; no outcome measure data analyses were conducted.
Time frame: Baseline and 12 weeks
Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) After 12 Weeks of Treatment
The study was terminated; no outcome measure data analyses were conducted.
Time frame: Baseline and 12 weeks
Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) After 12 Weeks of Treatment
The study was terminated; no outcome measure data analyses were conducted.
Time frame: Baseline and 12 weeks
First patient enrolled (FPE): 19 Sept 2007; Last patient enrolled (LPE) 22 Oct 2007. The protocol was terminated for Administrative Reasons
| Milestone | Simvastatin | Placebo |
|---|---|---|
| Started | 4 | 0 |
| Completed | 3 | 0 |
| Not completed | 1 | 0 |
The study was terminated; no outcome measure data analyses were conducted.
No measurements were reported for this outcome.
The study was terminated; no outcome measure data analyses were conducted.
No measurements were reported for this outcome.
The study was terminated; no outcome measure data analyses were conducted.
No measurements were reported for this outcome.
The study was terminated; no outcome measure data analyses were conducted.
No measurements were reported for this outcome.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Simvastatin | — | 0/4 (0%) | 0/4 (0%) |
| Placebo | — | — | — |
| Age, Categorical(Participants) | All Participants |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 4 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 4 |
| Male | 0 |
| Total Cholesterol(mg/dL) | All Participants |
|---|---|
| Mean | 176.67 ± 28.50 |
| Low Density Lipoprotein Cholesterol (LDL-C)(mg/dL) | All Participants |
|---|---|
| Mean | 105 ± 23.64 |
| High Density Lipoprotein Cholesterol (HDL-C)(mg/dL) | All Participants |
|---|---|
| Mean | 53 ± 10.15 |
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2007 to primary completion in Feb 2008, 4 months.
Results were first posted in Dec 2010, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Simvastatin
Lupus Erythematosus, Systemic →